image001.jpg
MARE NOSTRUM : Rapport financier annuel 2023
July 31, 2024 12:41 ET | MARE NOSTRUM
Rapport financier annuel 2023 de Mare Nostrum pour l'exercice clos le 31 décembre 2023. Pièce jointe MARE NOSTRUM - RFA 2023 complet ...
BD² ANNOUNCES NEW FU
BD² ANNOUNCES NEW FUNDING OPPORTUNITIES TO JOIN LANDMARK BIPOLAR DISORDER RESEARCH AND CLINICAL CARE NETWORK Washington, DC, July 18, 2024 (GLOBE NEWSWIRE) -- BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder today announced its second call for applications for clinic sites to join the BD²...
Correction: ORAPI :
Correction: ORAPI : Mise à disposition du Rapport Financier Annuel 2023
April 18, 2024 11:45 ET | ORAPI
Communiqué de presse         Lyon – Saint-Vulbas, le 18 avril 2024 à 17h30 Mise à disposition du rapport financier annuel 2023 ORAPI annonce avoir mis à la disposition du public et déposé auprès...
ORAPI : Mise à dispo
ORAPI : Mise à disposition du Rapport Financier Annuel 2023
April 18, 2024 11:30 ET | ORAPI
Communiqué de presse         Lyon – Saint-Vulbas, le 18 avril 2023 à 17h30 Mise à disposition du rapport financier annuel 2023 ORAPI annonce avoir mis à la disposition du public et déposé auprès de...
HIOLLE INDUSTRIES: m
HIOLLE INDUSTRIES: mise à disposition du Rapport Financier Annuel 2020
April 30, 2021 11:35 ET | HIOLLE INDUSTRIES
COMMUNIQUÉDE MISE A DISPOSITIONDU RAPPORT FINANCIER ANNUEL 2020 La société annonce avoir procédé en date du 30 Avril 2021 à la diffusion effective et intégrale et au dépôt auprès de l’Autorité des...
SPR Therapeutics LOGO 361 TM.jpg
SPRINT® PNS System Demonstrates the Important Role of the Multifidus in Treating Recurrent Low Back Pain Following RFA
March 02, 2021 10:45 ET | SPR Therapeutics, Inc.
CLEVELAND, March 02, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced publication of clinical data evaluating the impact of...
Logo.jpg
Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
April 15, 2020 08:30 ET | Celsion CORP
Independent Data Monitoring Committee is Expected to Meet in July 2020 to Evaluate Overall Survival Data LAWRENCEVILLE, N.J., April 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...
LOGO.jpg
Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus
January 06, 2020 06:55 ET | Interpace Biosciences, Inc.
Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary,...
Logo.jpg
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer
August 05, 2019 09:00 ET | Celsion CORP
Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...
logo.jpg
RFA and Seclore Announce Strategic Partnership to Deliver Data-Centric Security to Firms Worldwide
November 01, 2017 08:00 ET | Seclore
NEW YORK and SUNNYVALE, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- RFA and Seclore have agreed to integrate Seclore’s leading, data-centric security Rights Management solution into RFA’s managed...